TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31711041
Drug: Mézières method
Normalized name: Rezipres
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mézières method postural therapy (60 minutes, 2-3 sessions per week for 24 weeks)
Study: 31711041
Drug: Mézières method
Normalized name: Rezipres
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mézières method postural therapy
Study: 25535985
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg weekly (group A, 159 patients)
Study: 25535985
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg bi-weekly (group B, 164 patients)
Study: 25535985
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg weekly (group A)
Study: 25535985
Drug: Etanercept half-dose
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept half-dose regimen
Study: 31135225
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement (109 CFU/day) for 10 weeks
Study: 23339584
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) - up to 12 sessions in addition to usual care
Study: 16984012
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 (0.6 mg x kg(‐1))
Study: 16984012
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 (0.9 mg x kg(‐1))
Study: 19863739
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg x kg(‐1))
Study: 16984012
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 (0.15 mg x kg(‐1))
Study: 10754734
Drug: Endoventricular plasty
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoventricular plasty with patch (group A)
Study: 10754734
Drug: Endoventricular plasty
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoventricular plasty without patch (group B)
Study: 7739102
Drug: Midazolam-famotidine suppository
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam-famotidine suppository (0.5 mg.kg‐1 midazolam and 2 mg.kg‐1 famotidine)
Study: 7739102
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of hydroxyzine (1 mg.kg‐1)
Study: 7739102
Drug: Midazolam-famotidine suppository
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam-famotidine suppository
Study: 31838445
Drug: Nicotine e‐cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine e‐cigarette (8 mg/mL nicotine concentration)
Study: 29532718
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin fluorouracil followed by conventional radiotherapy
Study: 29532718
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy with concurrent cisplatin
Study: 18555546
Drug: Accelerated whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated whole brain irradiation (40 Gy in 20 fractions of 2 Gy twice daily)
Study: 18555546
Drug: Conventional whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional whole brain irradiation (20 Gy in 5 daily fractions)
Study: 14504153
Drug: 36 ml
Normalized name: ALCOHOL 177 mL in 236 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 ml of mepivacaine 10 mg x ml(‐1)
Study: 14504153
Drug: 28 ml
Normalized name: ethanol 0.28 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 ml of mepivacaine 10 mg x ml(‐1)
Study: 14504153
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of mepivacaine 10 mg x ml(‐1)
Study: 10389555
Drug: 1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine and hyaluronidase 75 units/ml
Study: 10389555
Drug: 1:1 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 mixture of 2% lignocaine and 0.5% bupivacaine and hyaluronidase 75 units/ml
Study: 1867082
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose treatment with trimethoprim
Study: 1867082
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course treatment with trimethoprim
Study: 23106658
Drug: Trichuris suis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichuris suis ova (2500 ova, 3 weekly doses over 6 months)
Study: 19715417
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg 3 times daily for 5 days)
Study: 17559753
Drug: Tramadolor (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadolor (200 mg, test formulation)
Study: 17559753
Drug: Ultram ER
Normalized name: Ultram ER
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultram ER (200 mg, reference formulation)
Study: 12038917
Drug: On-treatment analyses
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment analyses
Study: 9533973
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Doxepin
Study: 9533973
Drug: Nonresponse group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponse group (Fluoxetine or Doxepin)
Study: 2796855
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6‐thioguanine, cytosine arabinoside (TA) and cyclophosphamide/vincristine/cytosine arabinoside/prednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses.
Study: 25993906
Drug: Local trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local trial - inhalation of a hypercapnic gas mixture (5% CO2 in air) for 5 minutes with open circulation to active calf muscle, followed by PECO.
Study: 25993906
Drug: Systemic trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic trial - circulation through the muscle closed throughout exercise and PECO phases during hypercapnic gas inhalation.
Study: 25993906
Drug: Hyperoxia trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxia trial - inhalation of a hyperoxic hypercapnic gas mixture (95% O2 and 5% CO2) for 1 minute during PECO under systemic conditions.
Study: 23881421
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (100 mg capsules three times daily)
Study: 15028823
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of alendronate daily for 10 years
Study: 9443925
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of alendronate daily
Study: 15028823
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after discontinuation
Study: 8129541
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg SL
Study: 8129541
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg SL
Study: 3628610
Drug: d-amphetamine 20
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 20 mg/70 kg
Study: 31571403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirabegron 50 mg/d plus solifenacin 5 mg/d
Study: 31571403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirabegron 50 mg/d plus propiverine 20 mg/d
Study: 31571403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirabegron 50 mg/d plus imidafenacin 0.2 mg/d
Study: 31571403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirabegron 50 mg/d plus tolterodine 4 mg/d
Study: 31571403
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including mirabegron 50 mg once daily during screening)
Study: 26395781
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation with general therapy
Study: 26395781
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy (antibiotics only)
Study: 7769295
Drug: Vaccine adjuvanted
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine adjuvanted with alum
Study: 7769295
Drug: Vaccine adjuvanted
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine adjuvanted with alum plus 3-deacylated monophosphoryl lipid A (MPL)
Study: 7769295
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (alum and alum-MPL)
Study: 2284521
Drug: Metronidazole pessaries
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole pessaries (500 mg, once daily for 7 days)
Study: 94616
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg per day
Study: 3534848
Drug: Moduretic (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride)
Study: 6195479
Drug: NTG after
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG after 1 g of oral aspirin pretreatment
Study: 6195479
Drug: NTG after
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG after 8 days of aspirin, 500 mg every 48 h
Study: 6195479
Drug: NTG without
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG without aspirin pretreatment
Study: 31138568
Drug: ASN100 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN100 (combination of ASN‐1 and ASN‐2) at 3,600 or 8,000 mg
Study: 31138568
Drug: ASN100 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN100 (combination of ASN‐1 and ASN‐2)
Study: 31138568
Drug: ASN‐1 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN‐1 or ASN‐2 at 200, 600, 1,800, or 4,000 mg
Study: 31138568
Drug: Open-label ASN100
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label ASN100 at 3,600 or 8,000 mg
Study: 29563100
Drug: Tai chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai chi (12 or 24 weeks, once or twice weekly)
Study: 29563100
Drug: Tai chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai chi (24 weeks, twice weekly)
Study: 29563100
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (24 weeks, twice weekly)
Study: 22377744
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline at daily doses of 200, 300, 400, 600, and 800 mg for periods of 2‐10 months
Study: 11861971
Drug: Chlorpyrifos (CPF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpyrifos (CPF) administered orally at doses of 0.5-100 mg/kg in rats and 0.5-2 mg/kg in humans.
Study: 1977464
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg bd
Study: 1977464
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg bd
Study: 40798
Drug: metoprolol 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 10, 40 or 50 mg
Study: 40798
Drug: alprenolol 200
Normalized name: alprenolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprenolol 200 mg
Study: 17207073
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin cream (0.075%) applied unilaterally to the mental area, four times daily for 2 weeks
Study: 17207073
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin cream (0.075%)
Study: 15347608
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 10 mg/ml (1.5 ml) with glucose 300 mg/ml (0.5 ml)
Study: 15347608
Drug: Plain ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ropivacaine 7.5 mg/ml (2 ml)
Study: 3548803
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (AD and estimated weight reported)
Study: 31402538
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 5 mg, 10 mg, or 25 mg once daily
Study: 27658659
Drug: Antioxidant ice
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant ice cream (100 g containing dark cocoa powder, hazelnut, and green tea extracts)
Study: 27658659
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate ice cream (control ice cream)
Study: 23597082
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing and problem solving treatment (n=314)
Study: 21568075
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg t.i.d.)
Study: 21568075
Drug: Amlodipine +/‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine +/‐ ibuprofen
Study: 21568075
Drug: Lisinopril/hydrochlorothiazide +/‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide +/‐ piroxicam
Study: 11071672
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (cisplatin 60 mg/m² on day 1, etoposide 120 mg/m² on days 1-3, concurrent with radiotherapy 50.4 Gy in 28 fractions)
Study: 8851570
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg twice daily with food
Study: 8851570
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg once daily with food
Study: 8851570
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg twice daily fasting
Study: 8851570
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg single dose
Study: 8851570
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg single dose
Study: 8851570
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg twice daily with high-fat meal
Study: 1315665
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy plus plasmapheresis (plasma exchange)
Study: 1315665
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy alone
Study: 29903344
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy (DAPT) - aspirin 325 mg and clopidogrel 75 mg
Study: 29903344
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity warfarin plus aspirin (INR 1.5 to 2.0)
Study: 29903344
Drug: Standard warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard warfarin plus aspirin (INR 2.0 to 3.0)
Study: 8526179
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with specific hyposensitization (Abelló Lab., Spain) for 12 months
Study: 1483486
Drug: S-1452 50
Normalized name: HYMETELLOSE (50 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1452 50 mg
Study: 6529162
Drug: Alizapride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (50 mg)
Study: 21865319
Drug: Silymarin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (280 or 560 mg) every 8 hours for 7 days
Study: 11728684
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy (RT) at a dosage of 46 Gy
Study: 9106379
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diphenhydramine
Study: 28671879
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation (Vt 7 mL/kg-PEEP 5 mm Hg)
Study: 28671879
Drug: Traditional ventilation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional ventilation (Vt 9 mL/kg-PEEP 0 mm Hg)
Study: 23903901
Drug: Intrathecal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal normal saline 5 ml before intrathecal injection of 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Study: 23903901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 2.5 ml (12.5 mg) hyperbaric bupivacaine 0.5%
Study: 22652586
Drug: High OVA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High OVA IgA antibodies in colostrum
Study: 20736446
Drug: Hypothermia (cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia (cold saline infusion and endovascular cooling)
Study: 15845775
Drug: Anti-G suit
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-G suit inflated to 85 mmHg at 1 G
Study: 15845775
Drug: Anti-G suit
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-G suit inflated to 85 mmHg at 2 G
Study: 10047926
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine hydrochloride (APO)
Study: 10047926
Drug: Optimal doses
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal doses of carbidopa/levodopa
Study: 2251632
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) oral tablets used intravaginally
Study: 26616798
Drug: APC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC with medicine group (Esomeprazole 40 mg/d after APC treatment for 8 weeks)
Study: 26616798
Drug: APC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC with surgery group (Laparoscopic hiatal hernia repair and Nissen fundoplication after APC treatment)
Study: 19820283
Drug: P-OM3 4
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-OM3 4 g/day + fenofibrate 130 mg/day
Study: 19820283
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g/day corn oil) + fenofibrate 130 mg/day
Study: 17955091
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) such as gabapentin and pregabalin
Study: 11298069
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of racemic halofantrine once daily in the fasted state for 42 days
Study: 2647907
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine (less than 30 mg/day)
Study: 2647907
Drug: Low-dose levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose levodopa-carbidopa (less than 600/150 mg/day)
Study: 20568433
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Sulfasalazine
Study: 16891998
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT) and pill placebo
Study: 16891998
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moclobemide and group cognitive-behavioral therapy
Study: 16891998
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pill placebo)
Study: 2049967
Drug: Ofloxacin (OFX)
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin (OFX) treatment
Study: 2049967
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with Ofloxacin (OFX) and a single dose of aminoglycoside (isepamicin)
Study: 6128447
Drug: Rectal PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal PGE2
Study: 23438803
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 2% articaine (Group A)
Study: 23438803
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 2% articaine + 10 mL 0.75% ropivacaine (Group AR)
Study: 23438803
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.75% ropivacaine (Group R)
Study: 21543543
Drug: Early nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early nutrition program with varying diets during the neonatal period (no phosphate supplements provided)
Study: 16959618
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily from a dry powder inhaler (HandiHaler)